Sprenger, Heike
Rasinger, Josef Daniel
Hammer, Helen
Naboulsi, Wael
Zabinsky, Elke
Planatscher, Hannes
Schwarz, Michael
Poetz, Oliver
Braeuning, Albert http://orcid.org/0000-0003-3810-027X
Funding for this research was provided by:
Bundesinstitut für Risikobewertung (BfR)
Article History
Received: 14 April 2022
Accepted: 13 July 2022
First Online: 26 July 2022
Declarations
:
: The authors declare the following competing financial interest(s): HP and OP are shareholders of SIGNATOPE GmbH. SIGNATOPE offers assay development and service using MS-based immunoassay technology.